###begin article-title 0
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis
###end article-title 0
###begin title 1
Aims/hypothesis
###end title 1
###begin p 2
Cardiovascular disease contributes to mortality in type 1 diabetes mellitus, but the specific pathophysiological mechanisms remain to be established. We recently showed that the endothelial glycocalyx, a protective layer of proteoglycans covering the endothelium, is severely perturbed in type 1 diabetes, with concomitantly increased plasma levels of hyaluronan and hyaluronidase. In the present study, we evaluated the relationship between hyaluronan and hyaluronidase with carotid intima-media thickness (cIMT), an established surrogate marker for cardiovascular disease.
###end p 2
###begin title 3
Subjects and methods
###end title 3
###begin p 4
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Non-smoking type 1 diabetes patients without micro- or macrovascular complications and matched controls were recruited and cIMT of both carotid arteries was measured. To evaluate the relationship between cIMT and hyaluronan and hyaluronidase as well as other parameters, uni- or multivariate regression analyses were performed.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
We included 99 type 1 diabetes patients (age 10-72 years) and 99 age- and sex-matched controls. Mean cIMT, HbA1c, high sensitivity C-reactive protein, hyaluronan and hyaluronidase were significantly increased in type 1 diabetes vs controls. Plasma hyaluronan and hyaluronidase were correlated in type 1 diabetes. In univariate regression analyses, mean IMT was associated with plasma hyaluronan, age and male sex, whereas after multivariate analysis only age and sex remained statistically significant.
###end p 6
###begin title 7
Conclusions/interpretation
###end title 7
###begin p 8
###xml 33 41 <span type="species:ncbi:9606">patients</span>
We conclude that type 1 diabetes patients show structural changes of the arterial wall associated with increased hyaluronan metabolism. These data may lend further support to altered glycosaminoglycan metabolism in type 1 diabetes as a potential mechanism involved in accelerated atherogenesis.
###end p 8
###begin title 9
Keywords
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 424 425 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 599 600 599 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 694 695 694 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 880 881 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1055 1056 1055 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1058 1059 1058 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 1031 1039 <span type="species:ncbi:9606">patients</span>
Macro- and microvascular complications are a major cause of morbidity and mortality in patients with diabetes mellitus. While the macrovascular complications in patients with type 2 diabetes mellitus can partly be attributed to the increased prevalence of classic cardiovascular risk factors such as dyslipidaemia, these risk factors cannot explain the increased prevalence of atherosclerosis in type 1 diabetes mellitus [1-3]. Recent data demonstrated that hyperglycaemia itself may play a causative role. Thus, improved metabolic control is associated with a decreased macrovascular event rate [1-3]. However, the pathophysiology of glucose-associated atherogenesis remains to be elucidated [4, 5]. In recent years, the glycocalyx has emerged as a potential orchestrator of vascular homeostasis, which closely determines anti-adhesive and barrier properties of the vessel wall [6]. In line, we found that the endothelial glycocalyx is adversely affected by both acute and chronic hyperglycaemia in volunteers and type 1 diabetes patients, respectively [7, 8].
###end p 11
###begin p 12
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 689 690 689 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
Hyaluronan is a principal constituent of the glycocalyx and removal of the glycocalyx with hyaluronidase has been associated with increased vascular vulnerability towards atherogenic insults [9-11]. In animal models of type 1 diabetes, hyaluronidase activity has been shown to be increased and this correlated with increased carotid intima-media thickness (cIMT) [12-14]. In line with this, increased accumulation of hyaluronan within the arterial wall in type 1 diabetes patients correlated with vascular changes [15]. We recently found an acute increase in plasma hyaluronan coinciding with glycocalyx perturbation during a normo-insulinaemic-hyperglycaemic clamp in healthy volunteers [7]. Moreover, we observed an inverse correlation between plasma hyaluronan as well as plasma hyaluronidase and glycocalyx volume in patients with type 1 diabetes [8]. In this concept, hyperglycaemia-induced perturbation of hyaluronan metabolism, characterised by increased hyaluronidase activity with subsequent increased plasma hyaluronan levels, may indicate increased vascular vulnerability.
###end p 12
###begin p 13
###xml 150 158 <span type="species:ncbi:9606">patients</span>
In the present study, we set out to evaluate the potential relationship between structural changes of the carotid artery and hyaluronan metabolism in patients with uncomplicated type 1 diabetes.
###end p 13
###begin title 14
Subjects and methods
###end title 14
###begin p 15
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
###xml 592 600 <span type="species:ncbi:9606">patients</span>
We enrolled non-smoking Europid patients with type 1 diabetes, all without clinical signs of micro- or macrovascular disease. The patients were recruited from the Internal Medicine outpatient clinics of the Academic Medical Center and Onze Lieve Vrouwe Gasthuis in Amsterdam, the Netherlands. The presence of macrovascular disease, defined as ECG abnormalities or a history of cardiac, cerebral or peripheral vascular events, was an exclusion criterion for the study. Moreover, subjects with retinopathy, neuropathy, (micro) albuminuria, or hypertension were excluded from participation. All patients were on multiple daily injections of insulin with no other concomitant medication use. Matched non-smoking controls (selected for this study specifically) were unrelated volunteers of similar age and sex. Investigations of both study groups were randomly performed during the study period. Approval for the study was obtained from the Internal Review Board of the Academic Medical Center Amsterdam and all subjects gave written informed consent. The study was carried out in accordance with the principles of the Declaration of Helsinki.
###end p 15
###begin p 16
###xml 425 427 425 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
All measurements were performed after an overnight fast and in a quiet and air-conditioned room. Blood pressure was measured in triplicate and the last two measurements were averaged to obtain heart rate and systolic and diastolic blood pressure. The latter were averaged to calculate mean blood pressure. At baseline, blood samples were collected for determination of lipids, high sensitivity C-reactive protein (hsCRP), HbA1c, hyaluronan and hyaluronidase. The markers of hepatic function ASAT and ALAT (aspartate aminotransferase and alanine aminotransferase, respectively) were determined, since chronic liver disease is known to be associated with increased plasma hyaluronan levels [16]. After centrifugation (within 1 h after collection), aliquots were snap-frozen in liquid nitrogen and stored at -80degreesC.
###end p 16
###begin p 17
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Clinical chemistry</bold>
###xml 305 307 305 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Clinical chemistry Total cholesterol, HDL-cholesterol and triacylglycerol were measured by enzymatic methods (Roche Diagnostics, Basel, Switzerland). LDL-cholesterol was calculated using the Friedewald formula. ALAT and ASAT were measured by a pyridoxal-phosphate activation assay (Roche Diagnostics). HbA1c was measured using an HPLC (Reagens Bio-Rad Laboratories BV, the Netherlands) on a Variant II (Bio-Rad Laboratories). Total plasma hyaluronan and hsCRP levels were determined in duplicates by commercial ELISA (Echelon Biosciences, Salt Lake City, UT, USA and Roche, Bern, Switzerland, respectively). Plasma hyaluronidase levels were determined with a previously described assay [8, 17].
###end p 17
###begin p 18
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ultrasound B-mode protocol for cIMT measurement</bold>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1413 1420 <span type="species:ncbi:9606">patient</span>
Ultrasound B-mode protocol for cIMT measurement B-mode ultrasound imaging was used to visualise three carotid arterial wall segments comprising common carotid, bulb and internal of the left and right carotid arteries according to a previously published protocol [18, 19]. Subjects were scanned in the reclined position following a predetermined, standardised protocol. An Acuson 128 XP/10 v (Siemens, Erlangen, Germany) equipped with an L7 linear array transducer and extended frequency software was used. B-mode images were stored as 4:1 compressed jpeg files on a digital still recorder (SONY DKR-700 P). All scans were performed by the same sonographer. To investigate intra-sonographer reproducibility, ten study subjects were scanned in duplicate. These investigations enabled us to provide robust arterial wall thickness measurements (SD of the means of the paired cIMT measurements 0.05 mm; CV = 9.0%). One image analyst performed the analyses off-line with semi-automated quantitative and qualitative video image analysis software. Both the sonographer and the image analyst were blinded to the clinical status of the subjects. These images provided the cIMT data. Mean cIMT was defined as the mean cIMT of the right and left common carotid, the carotid bulb and the internal carotid far wall segments. For a given segment, cIMT was defined as the average of the right and left cIMT measurements. The per-patient averaged means of the cIMT values of segments was used for the primary analysis.
###end p 18
###begin p 19
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Statistical analysis</bold>
###xml 133 134 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 1206 1207 1206 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Statistical analysis Mean values of continuous variables between type 1 diabetes patients and controls were compared using Student's t test for independent samples. In the case of a skewed distribution the t test was performed on log-transformed values, while medians and interquartile ranges are presented. Chi-square tests were applied for comparison of distribution of dichotomous data. Correlation between hyaluronan and hyaluronidase was calculated by Spearman's rank coefficient (two-tailed). In this study our main interest was to find predictors for type 1 diabetes-associated atherosclerosis and vascular dysfunction. The relationship between the dependent variable cIMT on the one hand and other parameters (e.g. plasma hyaluronan) on the other was first explored univariably using linear regression analysis. For clinical variables and variables which revealed statistically significant correlations in the univariate analysis, estimates of cIMT adjusted for confounding were calculated with SPSS version 11.5 (Chicago, IL, USA). In addition, several multivariate models were built to explore the effects of age, sex and the statistically significant variables on cIMT. Throughout, a two tailed p value <0.05 was considered statistically significant.
###end p 19
###begin title 20
Results
###end title 20
###begin p 21
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 352 354 352 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 549 550 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 558 559 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 863 870 863 870 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 870 925 870 925 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22">Demographic and baseline parameters of the study cohort</p>
###xml 870 925 870 925 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="22">Demographic and baseline parameters of the study cohort</p></caption>
###xml 925 926 925 926 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 926 950 926 950 <th xmlns:xlink="http://www.w3.org/1999/xlink">Type 1 diabetes patients</th>
###xml 950 958 950 958 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls</th>
###xml 925 958 925 958 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th>Type 1 diabetes patients</th><th>Controls</th></tr>
###xml 925 958 925 958 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th>Type 1 diabetes patients</th><th>Controls</th></tr></thead>
###xml 958 980 958 980 <td xmlns:xlink="http://www.w3.org/1999/xlink">Number of participants</td>
###xml 980 982 980 982 <td xmlns:xlink="http://www.w3.org/1999/xlink">99</td>
###xml 982 984 982 984 <td xmlns:xlink="http://www.w3.org/1999/xlink">99</td>
###xml 958 984 958 984 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Number of participants</td><td>99</td><td>99</td></tr>
###xml 984 1001 984 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink">Sex (male/female)</td>
###xml 1001 1006 1001 1006 <td xmlns:xlink="http://www.w3.org/1999/xlink">44/55</td>
###xml 1006 1011 1006 1011 <td xmlns:xlink="http://www.w3.org/1999/xlink">44/55</td>
###xml 984 1011 984 1011 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Sex (male/female)</td><td>44/55</td><td>44/55</td></tr>
###xml 1011 1022 1011 1022 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 1022 1035 1022 1033 <td xmlns:xlink="http://www.w3.org/1999/xlink">32.8&#8201;&#177;&#8201;14.8</td>
###xml 1035 1048 1033 1044 <td xmlns:xlink="http://www.w3.org/1999/xlink">34.9&#8201;&#177;&#8201;16.4</td>
###xml 1011 1048 1011 1044 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>32.8&#8201;&#177;&#8201;14.8</td><td>34.9&#8201;&#177;&#8201;16.4</td></tr>
###xml 1048 1076 1044 1072 <td xmlns:xlink="http://www.w3.org/1999/xlink">Duration of diabetes (years)</td>
###xml 1076 1089 1072 1083 <td xmlns:xlink="http://www.w3.org/1999/xlink">16.4&#8201;&#177;&#8201;11.9</td>
###xml 1089 1090 1083 1084 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 1048 1090 1044 1084 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Duration of diabetes (years)</td><td>16.4&#8201;&#177;&#8201;11.9</td><td>&#8211;</td></tr>
###xml 1090 1114 1084 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink">Daily insulin dose (IU) </td>
###xml 1114 1127 1108 1119 <td xmlns:xlink="http://www.w3.org/1999/xlink">52.9&#8201;&#177;&#8201;20.3</td>
###xml 1127 1128 1119 1120 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#8211;</td>
###xml 1090 1128 1084 1120 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Daily insulin dose (IU) </td><td>52.9&#8201;&#177;&#8201;20.3</td><td>&#8211;</td></tr>
###xml 1128 1144 1120 1136 <td xmlns:xlink="http://www.w3.org/1999/xlink">Smoking (yes/no)</td>
###xml 1144 1148 1136 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/99</td>
###xml 1148 1152 1140 1144 <td xmlns:xlink="http://www.w3.org/1999/xlink">0/99</td>
###xml 1128 1152 1120 1144 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Smoking (yes/no)</td><td>0/99</td><td>0/99</td></tr>
###xml 1161 1162 1153 1154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1152 1163 1144 1155 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI (kg/m<sup>2</sup>)</td>
###xml 1163 1175 1155 1165 <td xmlns:xlink="http://www.w3.org/1999/xlink">23.4&#8201;&#177;&#8201;3.5</td>
###xml 1175 1187 1165 1175 <td xmlns:xlink="http://www.w3.org/1999/xlink">23.3&#8201;&#177;&#8201;3.6</td>
###xml 1152 1187 1144 1175 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI (kg/m<sup>2</sup>)</td><td>23.4&#8201;&#177;&#8201;3.5</td><td>23.3&#8201;&#177;&#8201;3.6</td></tr>
###xml 1187 1217 1175 1205 <td xmlns:xlink="http://www.w3.org/1999/xlink">Systolic blood pressure (mmHg)</td>
###xml 1217 1227 1205 1213 <td xmlns:xlink="http://www.w3.org/1999/xlink">123&#8201;&#177;&#8201;17</td>
###xml 1227 1237 1213 1221 <td xmlns:xlink="http://www.w3.org/1999/xlink">125&#8201;&#177;&#8201;20</td>
###xml 1187 1237 1175 1221 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Systolic blood pressure (mmHg)</td><td>123&#8201;&#177;&#8201;17</td><td>125&#8201;&#177;&#8201;20</td></tr>
###xml 1237 1268 1221 1252 <td xmlns:xlink="http://www.w3.org/1999/xlink">Diastolic blood pressure (mmHg)</td>
###xml 1268 1276 1252 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink">72&#8201;&#177;&#8201;9</td>
###xml 1276 1285 1258 1265 <td xmlns:xlink="http://www.w3.org/1999/xlink">73&#8201;&#177;&#8201;12</td>
###xml 1237 1285 1221 1265 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Diastolic blood pressure (mmHg)</td><td>72&#8201;&#177;&#8201;9</td><td>73&#8201;&#177;&#8201;12</td></tr>
###xml 1285 1307 1265 1287 <td xmlns:xlink="http://www.w3.org/1999/xlink">Heart rate (beats/min)</td>
###xml 1307 1318 1287 1296 <td xmlns:xlink="http://www.w3.org/1999/xlink">71&#8201;&#177;&#8201;11**</td>
###xml 1318 1328 1296 1304 <td xmlns:xlink="http://www.w3.org/1999/xlink">60&#8201;&#177;&#8201;14 </td>
###xml 1285 1328 1265 1304 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Heart rate (beats/min)</td><td>71&#8201;&#177;&#8201;11**</td><td>60&#8201;&#177;&#8201;14 </td></tr>
###xml 1328 1354 1304 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total cholesterol (mmol/l)</td>
###xml 1354 1365 1330 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.9&#8201;&#177;&#8201;0.9</td>
###xml 1365 1376 1339 1348 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.9&#8201;&#177;&#8201;1.0</td>
###xml 1328 1376 1304 1348 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total cholesterol (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.9</td><td>4.9&#8201;&#177;&#8201;1.0</td></tr>
###xml 1376 1400 1348 1372 <td xmlns:xlink="http://www.w3.org/1999/xlink">LDL-cholesterol (mmol/l)</td>
###xml 1400 1411 1372 1381 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.8&#8201;&#177;&#8201;0.7</td>
###xml 1411 1422 1381 1390 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.9&#8201;&#177;&#8201;0.8</td>
###xml 1376 1422 1348 1390 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LDL-cholesterol (mmol/l)</td><td>2.8&#8201;&#177;&#8201;0.7</td><td>2.9&#8201;&#177;&#8201;0.8</td></tr>
###xml 1422 1446 1390 1414 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL-cholesterol (mmol/l)</td>
###xml 1446 1457 1414 1423 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.6&#8201;&#177;&#8201;0.5</td>
###xml 1457 1468 1423 1432 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.5&#8201;&#177;&#8201;0.4</td>
###xml 1422 1468 1390 1432 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL-cholesterol (mmol/l)</td><td>1.6&#8201;&#177;&#8201;0.5</td><td>1.5&#8201;&#177;&#8201;0.4</td></tr>
###xml 1468 1492 1432 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink">Triacylglycerol (mmol/l)</td>
###xml 1492 1505 1456 1469 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9 (0.5&#8211;1.1)</td>
###xml 1505 1518 1469 1482 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.0 (0.5&#8211;1.2)</td>
###xml 1468 1518 1432 1482 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Triacylglycerol (mmol/l)</td><td>0.9 (0.5&#8211;1.1)</td><td>1.0 (0.5&#8211;1.2)</td></tr>
###xml 1518 1528 1482 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink">ASAT (U/l)</td>
###xml 1528 1538 1492 1502 <td xmlns:xlink="http://www.w3.org/1999/xlink">24 (21&#8211;27)</td>
###xml 1538 1548 1502 1512 <td xmlns:xlink="http://www.w3.org/1999/xlink">25 (21&#8211;29)</td>
###xml 1518 1548 1482 1512 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>ASAT (U/l)</td><td>24 (21&#8211;27)</td><td>25 (21&#8211;29)</td></tr>
###xml 1548 1558 1512 1522 <td xmlns:xlink="http://www.w3.org/1999/xlink">ALAT (U/l)</td>
###xml 1558 1568 1522 1532 <td xmlns:xlink="http://www.w3.org/1999/xlink">22 (15&#8211;28)</td>
###xml 1568 1578 1532 1542 <td xmlns:xlink="http://www.w3.org/1999/xlink">20 (14&#8211;24)</td>
###xml 1548 1578 1512 1542 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>ALAT (U/l)</td><td>22 (15&#8211;28)</td><td>20 (14&#8211;24)</td></tr>
###xml 1581 1583 1545 1547 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 1578 1587 1542 1551 <td xmlns:xlink="http://www.w3.org/1999/xlink">HbA<sub>1c</sub> (%)</td>
###xml 1587 1600 1551 1562 <td xmlns:xlink="http://www.w3.org/1999/xlink">8.3&#8201;&#177;&#8201;1.6**</td>
###xml 1600 1611 1562 1571 <td xmlns:xlink="http://www.w3.org/1999/xlink">5.1&#8201;&#177;&#8201;0.3</td>
###xml 1578 1611 1542 1571 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HbA<sub>1c</sub> (%)</td><td>8.3&#8201;&#177;&#8201;1.6**</td><td>5.1&#8201;&#177;&#8201;0.3</td></tr>
###xml 1611 1629 1571 1589 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hyaluronan (ng/ml)</td>
###xml 1629 1639 1589 1597 <td xmlns:xlink="http://www.w3.org/1999/xlink">78&#8201;&#177;&#8201;43*</td>
###xml 1639 1648 1597 1604 <td xmlns:xlink="http://www.w3.org/1999/xlink">60&#8201;&#177;&#8201;18</td>
###xml 1611 1648 1571 1604 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hyaluronan (ng/ml)</td><td>78&#8201;&#177;&#8201;43*</td><td>60&#8201;&#177;&#8201;18</td></tr>
###xml 1648 1668 1604 1624 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hyaluronidase (U/ml)</td>
###xml 1668 1680 1624 1634 <td xmlns:xlink="http://www.w3.org/1999/xlink">362&#8201;&#177;&#8201;23**</td>
###xml 1680 1690 1634 1642 <td xmlns:xlink="http://www.w3.org/1999/xlink">242&#8201;&#177;&#8201;13</td>
###xml 1648 1690 1604 1642 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hyaluronidase (U/ml)</td><td>362&#8201;&#177;&#8201;23**</td><td>242&#8201;&#177;&#8201;13</td></tr>
###xml 1690 1702 1642 1654 <td xmlns:xlink="http://www.w3.org/1999/xlink">hsCRP (mg/l)</td>
###xml 1702 1716 1654 1668 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.6 (0.4&#8211;2.9)*</td>
###xml 1716 1729 1668 1681 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.1 (0.2&#8211;2.0)</td>
###xml 1690 1729 1642 1681 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>hsCRP (mg/l)</td><td>2.6 (0.4&#8211;2.9)*</td><td>1.1 (0.2&#8211;2.0)</td></tr>
###xml 1729 1738 1681 1690 <td xmlns:xlink="http://www.w3.org/1999/xlink">cIMT (mm)</td>
###xml 1738 1753 1690 1703 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.61&#8201;&#177;&#8201;0.15**</td>
###xml 1753 1766 1703 1714 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.53&#8201;&#177;&#8201;0.12</td>
###xml 1729 1766 1681 1714 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>cIMT (mm)</td><td>0.61&#8201;&#177;&#8201;0.15**</td><td>0.53&#8201;&#177;&#8201;0.12</td></tr>
###xml 958 1766 958 1714 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Number of participants</td><td>99</td><td>99</td></tr><tr><td>Sex (male/female)</td><td>44/55</td><td>44/55</td></tr><tr><td>Age (years)</td><td>32.8&#8201;&#177;&#8201;14.8</td><td>34.9&#8201;&#177;&#8201;16.4</td></tr><tr><td>Duration of diabetes (years)</td><td>16.4&#8201;&#177;&#8201;11.9</td><td>&#8211;</td></tr><tr><td>Daily insulin dose (IU) </td><td>52.9&#8201;&#177;&#8201;20.3</td><td>&#8211;</td></tr><tr><td>Smoking (yes/no)</td><td>0/99</td><td>0/99</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>23.4&#8201;&#177;&#8201;3.5</td><td>23.3&#8201;&#177;&#8201;3.6</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>123&#8201;&#177;&#8201;17</td><td>125&#8201;&#177;&#8201;20</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>72&#8201;&#177;&#8201;9</td><td>73&#8201;&#177;&#8201;12</td></tr><tr><td>Heart rate (beats/min)</td><td>71&#8201;&#177;&#8201;11**</td><td>60&#8201;&#177;&#8201;14 </td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.9</td><td>4.9&#8201;&#177;&#8201;1.0</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>2.8&#8201;&#177;&#8201;0.7</td><td>2.9&#8201;&#177;&#8201;0.8</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.6&#8201;&#177;&#8201;0.5</td><td>1.5&#8201;&#177;&#8201;0.4</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>0.9 (0.5&#8211;1.1)</td><td>1.0 (0.5&#8211;1.2)</td></tr><tr><td>ASAT (U/l)</td><td>24 (21&#8211;27)</td><td>25 (21&#8211;29)</td></tr><tr><td>ALAT (U/l)</td><td>22 (15&#8211;28)</td><td>20 (14&#8211;24)</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>8.3&#8201;&#177;&#8201;1.6**</td><td>5.1&#8201;&#177;&#8201;0.3</td></tr><tr><td>Hyaluronan (ng/ml)</td><td>78&#8201;&#177;&#8201;43*</td><td>60&#8201;&#177;&#8201;18</td></tr><tr><td>Hyaluronidase (U/ml)</td><td>362&#8201;&#177;&#8201;23**</td><td>242&#8201;&#177;&#8201;13</td></tr><tr><td>hsCRP (mg/l)</td><td>2.6 (0.4&#8211;2.9)*</td><td>1.1 (0.2&#8211;2.0)</td></tr><tr><td>cIMT (mm)</td><td>0.61&#8201;&#177;&#8201;0.15**</td><td>0.53&#8201;&#177;&#8201;0.12</td></tr></tbody>
###xml 925 1766 925 1714 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>Type 1 diabetes patients</th><th>Controls</th></tr></thead><tbody><tr><td>Number of participants</td><td>99</td><td>99</td></tr><tr><td>Sex (male/female)</td><td>44/55</td><td>44/55</td></tr><tr><td>Age (years)</td><td>32.8&#8201;&#177;&#8201;14.8</td><td>34.9&#8201;&#177;&#8201;16.4</td></tr><tr><td>Duration of diabetes (years)</td><td>16.4&#8201;&#177;&#8201;11.9</td><td>&#8211;</td></tr><tr><td>Daily insulin dose (IU) </td><td>52.9&#8201;&#177;&#8201;20.3</td><td>&#8211;</td></tr><tr><td>Smoking (yes/no)</td><td>0/99</td><td>0/99</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>23.4&#8201;&#177;&#8201;3.5</td><td>23.3&#8201;&#177;&#8201;3.6</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>123&#8201;&#177;&#8201;17</td><td>125&#8201;&#177;&#8201;20</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>72&#8201;&#177;&#8201;9</td><td>73&#8201;&#177;&#8201;12</td></tr><tr><td>Heart rate (beats/min)</td><td>71&#8201;&#177;&#8201;11**</td><td>60&#8201;&#177;&#8201;14 </td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.9</td><td>4.9&#8201;&#177;&#8201;1.0</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>2.8&#8201;&#177;&#8201;0.7</td><td>2.9&#8201;&#177;&#8201;0.8</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.6&#8201;&#177;&#8201;0.5</td><td>1.5&#8201;&#177;&#8201;0.4</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>0.9 (0.5&#8211;1.1)</td><td>1.0 (0.5&#8211;1.2)</td></tr><tr><td>ASAT (U/l)</td><td>24 (21&#8211;27)</td><td>25 (21&#8211;29)</td></tr><tr><td>ALAT (U/l)</td><td>22 (15&#8211;28)</td><td>20 (14&#8211;24)</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>8.3&#8201;&#177;&#8201;1.6**</td><td>5.1&#8201;&#177;&#8201;0.3</td></tr><tr><td>Hyaluronan (ng/ml)</td><td>78&#8201;&#177;&#8201;43*</td><td>60&#8201;&#177;&#8201;18</td></tr><tr><td>Hyaluronidase (U/ml)</td><td>362&#8201;&#177;&#8201;23**</td><td>242&#8201;&#177;&#8201;13</td></tr><tr><td>hsCRP (mg/l)</td><td>2.6 (0.4&#8211;2.9)*</td><td>1.1 (0.2&#8211;2.0)</td></tr><tr><td>cIMT (mm)</td><td>0.61&#8201;&#177;&#8201;0.15**</td><td>0.53&#8201;&#177;&#8201;0.12</td></tr></tbody></table>
###xml 1766 1890 1714 1836 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="23">Data are means&#177;SD, except for triacylglycerol, ASAT, ALAT and hsCRP, which are expressed as median (inter-quartile range).</p>
###xml 1891 1892 1837 1838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1903 1904 1849 1850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1890 1948 1836 1894 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24">*<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 type 1 diabetes patients vs controls</p>
###xml 1766 1948 1714 1894 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="23">Data are means&#177;SD, except for triacylglycerol, ASAT, ALAT and hsCRP, which are expressed as median (inter-quartile range).</p><p textid="24">*<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 type 1 diabetes patients vs controls</p></table-wrap-foot>
###xml 863 1948 863 1894 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="22">Demographic and baseline parameters of the study cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>Type 1 diabetes patients</th><th>Controls</th></tr></thead><tbody><tr><td>Number of participants</td><td>99</td><td>99</td></tr><tr><td>Sex (male/female)</td><td>44/55</td><td>44/55</td></tr><tr><td>Age (years)</td><td>32.8&#8201;&#177;&#8201;14.8</td><td>34.9&#8201;&#177;&#8201;16.4</td></tr><tr><td>Duration of diabetes (years)</td><td>16.4&#8201;&#177;&#8201;11.9</td><td>&#8211;</td></tr><tr><td>Daily insulin dose (IU) </td><td>52.9&#8201;&#177;&#8201;20.3</td><td>&#8211;</td></tr><tr><td>Smoking (yes/no)</td><td>0/99</td><td>0/99</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>23.4&#8201;&#177;&#8201;3.5</td><td>23.3&#8201;&#177;&#8201;3.6</td></tr><tr><td>Systolic blood pressure (mmHg)</td><td>123&#8201;&#177;&#8201;17</td><td>125&#8201;&#177;&#8201;20</td></tr><tr><td>Diastolic blood pressure (mmHg)</td><td>72&#8201;&#177;&#8201;9</td><td>73&#8201;&#177;&#8201;12</td></tr><tr><td>Heart rate (beats/min)</td><td>71&#8201;&#177;&#8201;11**</td><td>60&#8201;&#177;&#8201;14 </td></tr><tr><td>Total cholesterol (mmol/l)</td><td>4.9&#8201;&#177;&#8201;0.9</td><td>4.9&#8201;&#177;&#8201;1.0</td></tr><tr><td>LDL-cholesterol (mmol/l)</td><td>2.8&#8201;&#177;&#8201;0.7</td><td>2.9&#8201;&#177;&#8201;0.8</td></tr><tr><td>HDL-cholesterol (mmol/l)</td><td>1.6&#8201;&#177;&#8201;0.5</td><td>1.5&#8201;&#177;&#8201;0.4</td></tr><tr><td>Triacylglycerol (mmol/l)</td><td>0.9 (0.5&#8211;1.1)</td><td>1.0 (0.5&#8211;1.2)</td></tr><tr><td>ASAT (U/l)</td><td>24 (21&#8211;27)</td><td>25 (21&#8211;29)</td></tr><tr><td>ALAT (U/l)</td><td>22 (15&#8211;28)</td><td>20 (14&#8211;24)</td></tr><tr><td>HbA<sub>1c</sub> (%)</td><td>8.3&#8201;&#177;&#8201;1.6**</td><td>5.1&#8201;&#177;&#8201;0.3</td></tr><tr><td>Hyaluronan (ng/ml)</td><td>78&#8201;&#177;&#8201;43*</td><td>60&#8201;&#177;&#8201;18</td></tr><tr><td>Hyaluronidase (U/ml)</td><td>362&#8201;&#177;&#8201;23**</td><td>242&#8201;&#177;&#8201;13</td></tr><tr><td>hsCRP (mg/l)</td><td>2.6 (0.4&#8211;2.9)*</td><td>1.1 (0.2&#8211;2.0)</td></tr><tr><td>cIMT (mm)</td><td>0.61&#8201;&#177;&#8201;0.15**</td><td>0.53&#8201;&#177;&#8201;0.12</td></tr></tbody></table><table-wrap-foot><p textid="23">Data are means&#177;SD, except for triacylglycerol, ASAT, ALAT and hsCRP, which are expressed as median (inter-quartile range).</p><p textid="24">*<italic>p</italic>&#8201;&lt;&#8201;0.05, **<italic>p</italic>&#8201;&lt;&#8201;0.01 type 1 diabetes patients vs controls</p></table-wrap-foot></table-wrap>
###xml 1948 1954 1894 1900 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1954 1955 1900 1901 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2065 2066 2011 2012 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1954 2149 1900 2095 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="25"><bold>a</bold> Relationship between plasma hyaluronan levels and plasma hyaluronidase activity in type 1 diabetes patients. <bold>b</bold> Relationship between plasma hyaluronan levels and cIMT in type 1 diabetes patients</p>
###xml 1954 2149 1900 2095 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="25"><bold>a</bold> Relationship between plasma hyaluronan levels and plasma hyaluronidase activity in type 1 diabetes patients. <bold>b</bold> Relationship between plasma hyaluronan levels and cIMT in type 1 diabetes patients</p></caption>
###xml 2149 2149 2095 2095 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2007_666_Fig1_HTML" id="MO1"/>
###xml 1948 2149 1894 2095 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="25"><bold>a</bold> Relationship between plasma hyaluronan levels and plasma hyaluronidase activity in type 1 diabetes patients. <bold>b</bold> Relationship between plasma hyaluronan levels and cIMT in type 1 diabetes patients</p></caption><graphic position="anchor" xlink:href="125_2007_666_Fig1_HTML" id="MO1"/></fig>
###xml 430 438 <span type="species:ncbi:9606">patients</span>
###xml 1928 1936 <span type="species:ncbi:9606">patients</span>
###xml 2055 2063 <span type="species:ncbi:9606">patients</span>
###xml 2141 2149 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of the 99 type 1 diabetes subjects and 99 matched controls are listed in Table 1. There was no significant difference between type 1 diabetes subjects and controls with regard to age, sex, BMI, systolic and diastolic blood pressure, liver function tests and cholesterol profile. However, we did observe increased values for HbA1c, heart rate, plasma hsCRP, hyaluronan and hyaluronidase in type 1 diabetes patients. A significant correlation was found between plasma hyaluronan and hyaluronidase activity in type 1 diabetes (r = 0.3, p < 0.05, see Fig. 1a). After exclusion of the highest hyaluronidase activity levels (levels >750 U/ml), the correlation between hyaluronan and hyaluronidase levels was still present. Liver function tests (ASAT and ALAT) were not significantly associated with plasma hyaluronan levels in type 1 diabetes. Table 1Demographic and baseline parameters of the study cohort Type 1 diabetes patientsControlsNumber of participants9999Sex (male/female)44/5544/55Age (years)32.8 +/- 14.834.9 +/- 16.4Duration of diabetes (years)16.4 +/- 11.9-Daily insulin dose (IU) 52.9 +/- 20.3-Smoking (yes/no)0/990/99BMI (kg/m2)23.4 +/- 3.523.3 +/- 3.6Systolic blood pressure (mmHg)123 +/- 17125 +/- 20Diastolic blood pressure (mmHg)72 +/- 973 +/- 12Heart rate (beats/min)71 +/- 11**60 +/- 14 Total cholesterol (mmol/l)4.9 +/- 0.94.9 +/- 1.0LDL-cholesterol (mmol/l)2.8 +/- 0.72.9 +/- 0.8HDL-cholesterol (mmol/l)1.6 +/- 0.51.5 +/- 0.4Triacylglycerol (mmol/l)0.9 (0.5-1.1)1.0 (0.5-1.2)ASAT (U/l)24 (21-27)25 (21-29)ALAT (U/l)22 (15-28)20 (14-24)HbA1c (%)8.3 +/- 1.6**5.1 +/- 0.3Hyaluronan (ng/ml)78 +/- 43*60 +/- 18Hyaluronidase (U/ml)362 +/- 23**242 +/- 13hsCRP (mg/l)2.6 (0.4-2.9)*1.1 (0.2-2.0)cIMT (mm)0.61 +/- 0.15**0.53 +/- 0.12Data are means+/-SD, except for triacylglycerol, ASAT, ALAT and hsCRP, which are expressed as median (inter-quartile range).*p < 0.05, **p < 0.01 type 1 diabetes patients vs controlsFig. 1a Relationship between plasma hyaluronan levels and plasma hyaluronidase activity in type 1 diabetes patients. b Relationship between plasma hyaluronan levels and cIMT in type 1 diabetes patients
###end p 21
###begin p 22
Demographic and baseline parameters of the study cohort
###end p 22
###begin p 23
Data are means+/-SD, except for triacylglycerol, ASAT, ALAT and hsCRP, which are expressed as median (inter-quartile range).
###end p 23
###begin p 24
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
*p < 0.05, **p < 0.01 type 1 diabetes patients vs controls
###end p 24
###begin p 25
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 111 112 111 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
a Relationship between plasma hyaluronan levels and plasma hyaluronidase activity in type 1 diabetes patients. b Relationship between plasma hyaluronan levels and cIMT in type 1 diabetes patients
###end p 25
###begin p 26
###xml 112 113 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 183 184 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 370 372 366 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 545 546 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 549 556 545 552 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 556 663 552 659 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Univariate and multivariate associations of cIMT with various risk factors in patients with type 1 diabetes</p>
###xml 556 663 552 659 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Univariate and multivariate associations of cIMT with various risk factors in patients with type 1 diabetes</p></caption>
###xml 663 672 659 668 <th xmlns:xlink="http://www.w3.org/1999/xlink">Parameter</th>
###xml 672 699 668 692 <th xmlns:xlink="http://www.w3.org/1999/xlink">Univariate &#946; coefficient</th>
###xml 699 700 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 699 706 692 699 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 706 735 699 725 <th xmlns:xlink="http://www.w3.org/1999/xlink">Multivariate &#946; coefficient</th>
###xml 735 736 725 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 735 742 725 732 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>p</italic> value</th>
###xml 663 742 659 732 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Parameter</th><th>Univariate &#946; coefficient</th><th><italic>p</italic> value</th><th>Multivariate &#946; coefficient</th><th><italic>p</italic> value</th></tr>
###xml 663 742 659 732 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>Parameter</th><th>Univariate &#946; coefficient</th><th><italic>p</italic> value</th><th>Multivariate &#946; coefficient</th><th><italic>p</italic> value</th></tr></thead>
###xml 742 753 732 743 <td xmlns:xlink="http://www.w3.org/1999/xlink">Female sex </td>
###xml 753 759 743 749 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.86*</td>
###xml 759 764 749 754 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.005</td>
###xml 764 771 754 761 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.048*</td>
###xml 771 776 761 766 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.029</td>
###xml 742 776 732 766 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Female sex </td><td align="center">&#8722;0.86*</td><td align="center">0.005</td><td align="center">&#8722;0.048*</td><td align="center">0.029</td></tr>
###xml 776 779 766 769 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age</td>
###xml 779 785 769 775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.007*</td>
###xml 785 790 775 780 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.001</td>
###xml 790 795 780 785 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.07*</td>
###xml 795 801 785 791 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.0001</td>
###xml 776 801 766 791 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age</td><td align="center">0.007*</td><td align="center">0.001</td><td align="center">0.07*</td><td align="center">0.0001</td></tr>
###xml 801 822 791 812 <td xmlns:xlink="http://www.w3.org/1999/xlink">Duration of diabetes </td>
###xml 822 828 812 818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.008*</td>
###xml 828 833 818 823 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.001</td>
###xml 833 839 823 829 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.110</td>
###xml 839 844 829 834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.340</td>
###xml 801 844 791 834 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Duration of diabetes </td><td align="center">0.008*</td><td align="center">0.001</td><td align="center">&#8722;0.110</td><td align="center">0.340</td></tr>
###xml 844 862 834 852 <td xmlns:xlink="http://www.w3.org/1999/xlink">Daily insulin dose</td>
###xml 862 868 852 858 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.001</td>
###xml 868 873 858 863 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.109</td>
###xml 873 873 863 863 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 873 873 863 863 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 844 873 834 863 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Daily insulin dose</td><td align="center">&#8722;0.001</td><td align="center">0.109</td><td/><td/></tr>
###xml 873 876 863 866 <td xmlns:xlink="http://www.w3.org/1999/xlink">BMI</td>
###xml 876 881 866 871 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.004</td>
###xml 881 886 871 876 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.433</td>
###xml 886 886 876 876 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 886 886 876 876 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 873 886 863 876 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>BMI</td><td align="center">0.004</td><td align="center">0.433</td><td/><td/></tr>
###xml 886 905 876 895 <td xmlns:xlink="http://www.w3.org/1999/xlink">Mean blood pressure</td>
###xml 905 911 895 901 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.004*</td>
###xml 911 916 901 906 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.004</td>
###xml 916 922 906 912 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.027</td>
###xml 922 927 912 917 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.726</td>
###xml 886 927 876 917 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Mean blood pressure</td><td align="center">0.004*</td><td align="center">0.004</td><td align="center">&#8722;0.027</td><td align="center">0.726</td></tr>
###xml 927 937 917 927 <td xmlns:xlink="http://www.w3.org/1999/xlink">Heart rate</td>
###xml 937 943 927 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.0001</td>
###xml 943 948 933 938 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.994</td>
###xml 948 948 938 938 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 948 948 938 938 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 927 948 917 938 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Heart rate</td><td align="center">0.0001</td><td align="center">0.994</td><td/><td/></tr>
###xml 948 965 938 955 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total cholesterol</td>
###xml 965 970 955 960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.016</td>
###xml 970 975 960 965 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.366</td>
###xml 975 975 965 965 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 975 975 965 965 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 948 975 938 965 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total cholesterol</td><td align="center">0.016</td><td align="center">0.366</td><td/><td/></tr>
###xml 975 990 965 980 <td xmlns:xlink="http://www.w3.org/1999/xlink">LDL-cholesterol</td>
###xml 990 995 980 985 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.021</td>
###xml 995 1000 985 990 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.321</td>
###xml 1000 1000 990 990 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1000 1000 990 990 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 975 1000 965 990 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>LDL-cholesterol</td><td align="center">0.021</td><td align="center">0.321</td><td/><td/></tr>
###xml 1000 1015 990 1005 <td xmlns:xlink="http://www.w3.org/1999/xlink">HDL-cholesterol</td>
###xml 1015 1020 1005 1010 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.026</td>
###xml 1020 1025 1010 1015 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.416</td>
###xml 1025 1025 1015 1015 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1025 1025 1015 1015 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1000 1025 990 1015 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HDL-cholesterol</td><td align="center">0.026</td><td align="center">0.416</td><td/><td/></tr>
###xml 1025 1040 1015 1030 <td xmlns:xlink="http://www.w3.org/1999/xlink">Triacylglycerol</td>
###xml 1040 1046 1030 1036 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.054</td>
###xml 1046 1051 1036 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.076</td>
###xml 1051 1051 1041 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1051 1051 1041 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1025 1051 1015 1041 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Triacylglycerol</td><td align="center">&#8722;0.054</td><td align="center">0.076</td><td/><td/></tr>
###xml 1051 1055 1041 1045 <td xmlns:xlink="http://www.w3.org/1999/xlink">ASAT</td>
###xml 1055 1060 1045 1050 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.037</td>
###xml 1060 1065 1050 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.615</td>
###xml 1065 1065 1055 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1065 1065 1055 1055 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1051 1065 1041 1055 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>ASAT</td><td align="center">0.037</td><td align="center">0.615</td><td/><td/></tr>
###xml 1065 1069 1055 1059 <td xmlns:xlink="http://www.w3.org/1999/xlink">ALAT</td>
###xml 1069 1075 1059 1065 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.019</td>
###xml 1075 1080 1065 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.589</td>
###xml 1080 1080 1070 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1080 1080 1070 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1065 1080 1055 1070 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>ALAT</td><td align="center">&#8722;0.019</td><td align="center">0.589</td><td/><td/></tr>
###xml 1083 1085 1073 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 1080 1085 1070 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink">HbA<sub>1c</sub></td>
###xml 1085 1091 1075 1081 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.008</td>
###xml 1091 1096 1081 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.441</td>
###xml 1096 1096 1086 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1096 1096 1086 1086 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1080 1096 1070 1086 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>HbA<sub>1c</sub></td><td align="center">&#8722;0.008</td><td align="center">0.441</td><td/><td/></tr>
###xml 1096 1106 1086 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hyaluronan</td>
###xml 1106 1112 1096 1102 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.126*</td>
###xml 1112 1117 1102 1107 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.001</td>
###xml 1117 1122 1107 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.116</td>
###xml 1122 1127 1112 1117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.130</td>
###xml 1096 1127 1086 1117 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hyaluronan</td><td align="center">0.126*</td><td align="center">0.001</td><td align="center">0.116</td><td align="center">0.130</td></tr>
###xml 1127 1140 1117 1130 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hyaluronidase</td>
###xml 1140 1145 1130 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.036</td>
###xml 1145 1150 1135 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.731</td>
###xml 1150 1150 1140 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1150 1150 1140 1140 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1127 1150 1117 1140 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hyaluronidase</td><td align="center">0.036</td><td align="center">0.731</td><td/><td/></tr>
###xml 1150 1155 1140 1145 <td xmlns:xlink="http://www.w3.org/1999/xlink">hsCRP</td>
###xml 1155 1161 1145 1151 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">&#8722;0.013</td>
###xml 1161 1166 1151 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="center">0.306</td>
###xml 1166 1166 1156 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1166 1166 1156 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1150 1166 1140 1156 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>hsCRP</td><td align="center">&#8722;0.013</td><td align="center">0.306</td><td/><td/></tr>
###xml 742 1166 732 1156 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Female sex </td><td align="center">&#8722;0.86*</td><td align="center">0.005</td><td align="center">&#8722;0.048*</td><td align="center">0.029</td></tr><tr><td>Age</td><td align="center">0.007*</td><td align="center">0.001</td><td align="center">0.07*</td><td align="center">0.0001</td></tr><tr><td>Duration of diabetes </td><td align="center">0.008*</td><td align="center">0.001</td><td align="center">&#8722;0.110</td><td align="center">0.340</td></tr><tr><td>Daily insulin dose</td><td align="center">&#8722;0.001</td><td align="center">0.109</td><td/><td/></tr><tr><td>BMI</td><td align="center">0.004</td><td align="center">0.433</td><td/><td/></tr><tr><td>Mean blood pressure</td><td align="center">0.004*</td><td align="center">0.004</td><td align="center">&#8722;0.027</td><td align="center">0.726</td></tr><tr><td>Heart rate</td><td align="center">0.0001</td><td align="center">0.994</td><td/><td/></tr><tr><td>Total cholesterol</td><td align="center">0.016</td><td align="center">0.366</td><td/><td/></tr><tr><td>LDL-cholesterol</td><td align="center">0.021</td><td align="center">0.321</td><td/><td/></tr><tr><td>HDL-cholesterol</td><td align="center">0.026</td><td align="center">0.416</td><td/><td/></tr><tr><td>Triacylglycerol</td><td align="center">&#8722;0.054</td><td align="center">0.076</td><td/><td/></tr><tr><td>ASAT</td><td align="center">0.037</td><td align="center">0.615</td><td/><td/></tr><tr><td>ALAT</td><td align="center">&#8722;0.019</td><td align="center">0.589</td><td/><td/></tr><tr><td>HbA<sub>1c</sub></td><td align="center">&#8722;0.008</td><td align="center">0.441</td><td/><td/></tr><tr><td>Hyaluronan</td><td align="center">0.126*</td><td align="center">0.001</td><td align="center">0.116</td><td align="center">0.130</td></tr><tr><td>Hyaluronidase</td><td align="center">0.036</td><td align="center">0.731</td><td/><td/></tr><tr><td>hsCRP</td><td align="center">&#8722;0.013</td><td align="center">0.306</td><td/><td/></tr></tbody>
###xml 663 1166 659 1156 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Univariate &#946; coefficient</th><th><italic>p</italic> value</th><th>Multivariate &#946; coefficient</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Female sex </td><td align="center">&#8722;0.86*</td><td align="center">0.005</td><td align="center">&#8722;0.048*</td><td align="center">0.029</td></tr><tr><td>Age</td><td align="center">0.007*</td><td align="center">0.001</td><td align="center">0.07*</td><td align="center">0.0001</td></tr><tr><td>Duration of diabetes </td><td align="center">0.008*</td><td align="center">0.001</td><td align="center">&#8722;0.110</td><td align="center">0.340</td></tr><tr><td>Daily insulin dose</td><td align="center">&#8722;0.001</td><td align="center">0.109</td><td/><td/></tr><tr><td>BMI</td><td align="center">0.004</td><td align="center">0.433</td><td/><td/></tr><tr><td>Mean blood pressure</td><td align="center">0.004*</td><td align="center">0.004</td><td align="center">&#8722;0.027</td><td align="center">0.726</td></tr><tr><td>Heart rate</td><td align="center">0.0001</td><td align="center">0.994</td><td/><td/></tr><tr><td>Total cholesterol</td><td align="center">0.016</td><td align="center">0.366</td><td/><td/></tr><tr><td>LDL-cholesterol</td><td align="center">0.021</td><td align="center">0.321</td><td/><td/></tr><tr><td>HDL-cholesterol</td><td align="center">0.026</td><td align="center">0.416</td><td/><td/></tr><tr><td>Triacylglycerol</td><td align="center">&#8722;0.054</td><td align="center">0.076</td><td/><td/></tr><tr><td>ASAT</td><td align="center">0.037</td><td align="center">0.615</td><td/><td/></tr><tr><td>ALAT</td><td align="center">&#8722;0.019</td><td align="center">0.589</td><td/><td/></tr><tr><td>HbA<sub>1c</sub></td><td align="center">&#8722;0.008</td><td align="center">0.441</td><td/><td/></tr><tr><td>Hyaluronan</td><td align="center">0.126*</td><td align="center">0.001</td><td align="center">0.116</td><td align="center">0.130</td></tr><tr><td>Hyaluronidase</td><td align="center">0.036</td><td align="center">0.731</td><td/><td/></tr><tr><td>hsCRP</td><td align="center">&#8722;0.013</td><td align="center">0.306</td><td/><td/></tr></tbody></table>
###xml 1167 1168 1157 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1166 1212 1156 1202 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">*<italic>p</italic>&#8201;&lt;&#8201;0.05 type 1 diabetes patients vs controls</p>
###xml 1166 1212 1156 1202 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">*<italic>p</italic>&#8201;&lt;&#8201;0.05 type 1 diabetes patients vs controls</p></table-wrap-foot>
###xml 549 1212 545 1202 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="27">Univariate and multivariate associations of cIMT with various risk factors in patients with type 1 diabetes</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Parameter</th><th>Univariate &#946; coefficient</th><th><italic>p</italic> value</th><th>Multivariate &#946; coefficient</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Female sex </td><td align="center">&#8722;0.86*</td><td align="center">0.005</td><td align="center">&#8722;0.048*</td><td align="center">0.029</td></tr><tr><td>Age</td><td align="center">0.007*</td><td align="center">0.001</td><td align="center">0.07*</td><td align="center">0.0001</td></tr><tr><td>Duration of diabetes </td><td align="center">0.008*</td><td align="center">0.001</td><td align="center">&#8722;0.110</td><td align="center">0.340</td></tr><tr><td>Daily insulin dose</td><td align="center">&#8722;0.001</td><td align="center">0.109</td><td/><td/></tr><tr><td>BMI</td><td align="center">0.004</td><td align="center">0.433</td><td/><td/></tr><tr><td>Mean blood pressure</td><td align="center">0.004*</td><td align="center">0.004</td><td align="center">&#8722;0.027</td><td align="center">0.726</td></tr><tr><td>Heart rate</td><td align="center">0.0001</td><td align="center">0.994</td><td/><td/></tr><tr><td>Total cholesterol</td><td align="center">0.016</td><td align="center">0.366</td><td/><td/></tr><tr><td>LDL-cholesterol</td><td align="center">0.021</td><td align="center">0.321</td><td/><td/></tr><tr><td>HDL-cholesterol</td><td align="center">0.026</td><td align="center">0.416</td><td/><td/></tr><tr><td>Triacylglycerol</td><td align="center">&#8722;0.054</td><td align="center">0.076</td><td/><td/></tr><tr><td>ASAT</td><td align="center">0.037</td><td align="center">0.615</td><td/><td/></tr><tr><td>ALAT</td><td align="center">&#8722;0.019</td><td align="center">0.589</td><td/><td/></tr><tr><td>HbA<sub>1c</sub></td><td align="center">&#8722;0.008</td><td align="center">0.441</td><td/><td/></tr><tr><td>Hyaluronan</td><td align="center">0.126*</td><td align="center">0.001</td><td align="center">0.116</td><td align="center">0.130</td></tr><tr><td>Hyaluronidase</td><td align="center">0.036</td><td align="center">0.731</td><td/><td/></tr><tr><td>hsCRP</td><td align="center">&#8722;0.013</td><td align="center">0.306</td><td/><td/></tr></tbody></table><table-wrap-foot><p textid="28">*<italic>p</italic>&#8201;&lt;&#8201;0.05 type 1 diabetes patients vs controls</p></table-wrap-foot></table-wrap>
###xml 413 421 <span type="species:ncbi:9606">patients</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
###xml 1192 1200 <span type="species:ncbi:9606">patients</span>
Mean cIMT was increased in the type 1 diabetes group compared with controls (0.61 +/- 0.15 vs 0.53 +/- 0.12 mm, p < 0.001). In type 1 diabetes subjects plasma hyaluronan levels (Fig. 1b), age, male sex, duration of diabetes and mean blood pressure were positively correlated with mean cIMT in univariate analysis. No dose-dependent relationship between insulin dose, HbA1c levels and mean cIMT was found in these patients. However, upon multivariate linear regression analysis only age and sex remained significantly associated with cIMT (Table 2). Table 2Univariate and multivariate associations of cIMT with various risk factors in patients with type 1 diabetesParameterUnivariate beta coefficientp valueMultivariate beta coefficientp valueFemale sex -0.86*0.005-0.048*0.029Age0.007*0.0010.07*0.0001Duration of diabetes 0.008*0.001-0.1100.340Daily insulin dose-0.0010.109BMI0.0040.433Mean blood pressure0.004*0.004-0.0270.726Heart rate0.00010.994Total cholesterol0.0160.366LDL-cholesterol0.0210.321HDL-cholesterol0.0260.416Triacylglycerol-0.0540.076ASAT0.0370.615ALAT-0.0190.589HbA1c-0.0080.441Hyaluronan0.126*0.0010.1160.130Hyaluronidase0.0360.731hsCRP-0.0130.306*p < 0.05 type 1 diabetes patients vs controls
###end p 26
###begin p 27
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Univariate and multivariate associations of cIMT with various risk factors in patients with type 1 diabetes
###end p 27
###begin p 28
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 26 34 <span type="species:ncbi:9606">patients</span>
*p < 0.05 type 1 diabetes patients vs controls
###end p 28
###begin title 29
Discussion
###end title 29
###begin p 30
###xml 42 50 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
In line with expectation, type 1 diabetes patients were characterised by structural changes of the arterial wall. In addition, we observed significant elevations of plasma hyaluronan and hyaluronidase activity levels in type 1 diabetes patients, whereas hyaluronan was correlated to cIMT. These present data imply that disturbances of hyaluronan metabolism may be associated with vascular damage in type 1 diabetes patients.
###end p 30
###begin p 31
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Intima-media thickness in type 1 diabetes</bold>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 734 736 734 736 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 854 856 854 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 983 984 983 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 986 987 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1020 1022 1020 1022 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 1303 1305 1303 1305 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
###xml 927 935 <span type="species:ncbi:9606">patients</span>
###xml 1101 1109 <span type="species:ncbi:9606">patients</span>
Intima-media thickness in type 1 diabetes We observed a significant increase in cIMT in type 1 diabetes patients without micro- or macro-vascular complications compared with controls and confirmed that male sex is associated with an increased cIMT [3]. Despite the cross-sectional design of our study, this finding is compatible with data from the longitudinal DCCT study [3]. LDL-cholesterol was not associated with cIMT progression in the DCCT cohort, underscoring a potential role for hyperglycaemia in diabetic atherogenesis [1, 20, 21]. In contrast to the DCCT findings, we did not find a correlation between cIMT and glycaemic status. This apparent discrepancy may have several explanations. First, a single determination of HbA1c in our study may not be a reliable reflection of glycaemic excursions over the last months to years. In the DCCT, HbA1c was evaluated repetitively in a prospective cohort of type 1 diabetes patients, all receiving an intensive treatment regimen [1, 3]. Under these circumstances, HbA1c was predictive of cIMT progression over the next 4 years. Second, the elderly patients in our cohort may have been exposed to longer periods of poorly controlled diabetes followed by more intensive treatment regimens only in the last few years. As a consequence, their present HbA1c levels may have underestimated long-term glycaemic exposure.
###end p 31
###begin p 32
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Hyaluronan metabolism and type 1 diabetes</bold>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1914 1916 1914 1916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1918 1920 1918 1920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 2134 2136 2134 2136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 2138 2140 2138 2140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 623 631 <span type="species:ncbi:9606">patients</span>
###xml 1377 1385 <span type="species:ncbi:9606">patients</span>
###xml 1904 1912 <span type="species:ncbi:9606">patients</span>
###xml 2124 2132 <span type="species:ncbi:9606">patients</span>
Hyaluronan metabolism and type 1 diabetes Hyaluronan is the principal constituent of endothelial glycocalyx as well as the extra-cellular matrix [7-10, 14, 15, 22]. Since the glycocalyx is a principal determinant of vascular permeability for macromolecules (e.g. lipoproteins), glycocalyx loss may contribute to the increased transvascular leakage of lipoproteins in patients with type 1 diabetes [20]. Indeed exposure of the carotid artery to atherogenic challenges in mice resulted in increased plasma hyaluronan shedding, concomitant loss of endothelial glycocalyx and increased cIMT [23, 24]. In line, we observed that patients with uncomplicated type 1 diabetes have a profound reduction of endothelial glycocalyx, which was associated with increased plasma hyaluronan and hyaluronidase levels [8]. In fact, in the present study we find a positive correlation between plasma hyaluronan and cIMT thickness. Upon multivariate analysis this correlation was lost, most likely due to the fact that age and sex are very closely associated with cIMT, thus attenuating the predictive value of hyaluronan [19]. We did not find a relationship between chronic inflammation as measured by hsCRP and plasma hyaluronan in type 1 diabetes. Therefore further studies are needed to evaluate the effect of other inflammatory markers (e.g. leucocyte count) on hyaluronan metabolism in these patients.Collectively, the present finding implies that hyperglycaemia may elicit alterations in hyaluronan metabolism, which are likely to reflect glycocalyx perturbation. The latter facilitates a wide array of pro-atherogenic effects, including vascular dysfunction and increased permeability of the vessel wall for, for example, lipoproteins. In line, aggregation of calcium with hyaluronan (and other subendothelial glycosaminoglycans) could enhance ectopic calcification of the cIMT, which is increased in type 1 diabetes patients [25, 26]. It would be interesting to investigate whether therapeutic intervention aimed at this disturbed hyaluronan metabolism in type 1 diabetes has the potential to reverse the pro-atherogenic state in these patients [27, 28].
###end p 32
###begin p 33
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Study limitations</bold>
###xml 236 238 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c</sub>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1011 1012 1011 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
Study limitations Several methodological aspects of our study merit caution. We did not determine fasting plasma glucose levels in our type 1 diabetes subjects, therefore we were only able to study markers of chronic hyperglycaemia (HbA1c) on vascular dysfunction. Moreover, the observational nature of our study combined with the use of surrogate markers of future vascular disease can be considered a weakness. However, solid evidence exists that changes in arterial wall function are predictive of cardiovascular outcome [29, 30]. In addition, reproducibility of the measurements was excellent, since a single ultrasound machine was used, one experienced sonographer performed all ultrasonography and images were analysed by a single reader. To reduce variability further, image analysis software automatically investigated each measurement.Finally endothelial glycocalyx also comprises other glycosaminoglycans such as syndecan, chondroitin sulphate and heparan sulphate, which all have their own function [6, 31]. Since hyaluronan and heparan sulphate are important in shear stress-mediated nitric oxide production, which is inextricably entangled with atherosclerosis, further research is needed to explore the role of these other endothelial glycocalyx compounds on diabetes mellitus associated vascular dysfunction.
###end p 33
###begin title 34
Acknowledgements
###end title 34
###begin p 35
This study was partly funded by a research grant from the Netherlands Heart Foundation to E. S. G. Stroes (2006B088). H. Vink is an established investigator of the Netherlands Heart Foundation (2005T037). J. J. P. Kastelein is a clinical established investigator of the Netherlands Heart Foundation (2000D039).
###end p 35
###begin p 36
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest All authors declare that there is no conflict of interest.
###end p 36
###begin title 37
References
###end title 37
###begin article-title 38
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
###end article-title 38
###begin article-title 39
###xml 39 47 <span type="species:ncbi:9606">patients</span>
High risk of cardiovascular disease in patients with type 1 diabetes in the UK: a cohort study using the general practice research database
###end article-title 39
###begin article-title 40
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus
###end article-title 40
###begin article-title 41
Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes
###end article-title 41
###begin article-title 42
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial
###end article-title 42
###begin article-title 43
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo
###end article-title 43
###begin article-title 44
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes
###end article-title 44
###begin article-title 45
Permeation of the luminal capillary glycocalyx is determined by hyaluronan
###end article-title 45
###begin article-title 46
The endothelial glycocalyx protects against myocardial edema
###end article-title 46
###begin article-title 47
Oxidized lipoproteins degrade the endothelial surface layer: implications for platelet-endothelial cell adhesion
###end article-title 47
###begin article-title 48
###xml 67 71 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Circulating hyaluronan and hyaluronidase are increased in diabetic rats
###end article-title 48
###begin article-title 49
###xml 103 107 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Enhanced activity of serum and urinary hyaluronidases in streptozotocin-induced diabetic Wistar and GK rats
###end article-title 49
###begin article-title 50
Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis
###end article-title 50
###begin article-title 51
###xml 26 31 <span type="species:ncbi:9606">human</span>
Glycosaminoglycans in the human aorta in diabetes mellitus: a study of tunica media from areas with and without atherosclerotic plaque
###end article-title 51
###begin article-title 52
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Is serum hyaluronan a helpful tool in the management of patients with liver diseases?
###end article-title 52
###begin article-title 53
A microtiter-based assay for hyaluronidase activity not requiring specialized reagents
###end article-title 53
###begin article-title 54
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis
###end article-title 54
###begin article-title 55
###xml 41 49 <span type="species:ncbi:9606">children</span>
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial
###end article-title 55
###begin article-title 56
Increased transvascular low density lipoprotein transport in insulin dependent diabetes: a mechanistic model for development of atherosclerosis
###end article-title 56
###begin article-title 57
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions
###end article-title 57
###begin article-title 58
###xml 52 57 <span type="species:ncbi:9606">human</span>
Distribution of glycosaminoglycans in the intima of human aortas: changes in atherosclerosis and diabetes mellitus
###end article-title 58
###begin article-title 59
Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion
###end article-title 59
###begin article-title 60
###xml 98 104 <span type="species:ncbi:10090">murine</span>
Atherogenic region and diet diminish glycocalyx dimension and increase intima media ratios at the murine carotid artery bifurcation
###end article-title 60
###begin article-title 61
Medial artery calcification. A neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus
###end article-title 61
###begin article-title 62
###xml 97 102 <span type="species:ncbi:9606">human</span>
Decorin promotes aortic smooth muscle cell calcification and colocalizes to calcified regions in human atherosclerotic lesions
###end article-title 62
###begin article-title 63
Inhibitors of the hyaluronidases
###end article-title 63
###begin article-title 64
###xml 0 1 0 1 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
l-Ascorbic acid 6-hexadecanoate, a potent hyaluronidase inhibitor. X-ray structure and molecular modeling of enzyme-inhibitor complexes
###end article-title 64
###begin article-title 65
Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group
###end article-title 65
###begin article-title 66
The role of carotid arterial intima-media thickness in predicting clinical coronary events
###end article-title 66
###begin article-title 67
Mechanotransduction and the glycocalyx
###end article-title 67
###begin title 68
Abbreviations
###end title 68
###begin p 69
alanine aminotransferase
###end p 69
###begin p 70
aspartate aminotransferase
###end p 70
###begin p 71
carotid intima-media thickness
###end p 71
###begin p 72
high sensitivity C-reactive protein
###end p 72

